Genomic profiling in the randomised controlled phase III COMPOSE trial of Lu-177 edotreotide for well-differentiated aggressive grade 2/3 gastroenteropancreatic-neuroendocrine tumors

#3964

Introduction: Targeted radiopharmaceutical therapy (RPT) has demonstrated potential in treatment of gastroenteropancreatic-neuroendocrine tumors (GEP-NETs). However, RPT exhibits variable outcomes and lacks tools to predict individual efficacy. To address the latter, a genomic profiling analysis was included in the randomised, controlled, open-label, phase III COMPOSE trial of Lu-177 edotreotide vs. best standard of care (CAPTEM, FOLFOX or everolimus) in patients with well differentiated, aggressive, G2/G3 somatostatin receptor-positive GEP-NETs.

Aim(s): The genomic sub-study aims to identify predictive and prognostic genomic markers on multiple omics levels to improve understanding of tumour progression, RPT response and guide individualised NET treatment.

Materials and methods: Participation in the sub-study is optional and does not affect disease management or trial procedures. The genomic signatures of GEP-NETs are analysed by whole exome sequencing to understand predisposition and mutational drivers. Tumor biopsies (historical or fresh) and blood samples (collected before, during treatment, and at disease progression) are analysed to identify relevant genomic expression signatures.

Conference:

Presenting Author:

Authors: Srirajaskanthan R, Capdevila J, Halfdanarson T, Halperin D, Herrmann K,

Keywords: radiopharmaceutical therapy, genomic, Lu-177 edotreotide, gastroenteropancreatic, tumor, neuroendocrine,